Previous 10 | Next 10 |
GW Pharmaceuticals plc (GWPH) Q2 2019 Earnings Conference Call August 6, 2019 4:30 PM ET Company Participants Stephen Schultz – Vice President-Investor Relations Justin Gover – Chief Executive Officer Darren Cline – U.S. Chief Commercial Officer Chris Tovey...
GW Pharmaceuticals (NASDAQ: GWPH ) Q2 results : More news on: GW Pharmaceuticals plc, Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more ...
GW Pharmaceuticals (NASDAQ: GWPH ): Q2 GAAP EPS of $0.21 beats by $0.23 . Revenue of $72.04M (+2083.0% Y/Y) beats by $26.47M . Shares +7% . Press Release More news on: GW Pharmaceuticals plc, Earnings news and commentary, Stocks on the move, Healthcare stocks news,
- Epidiolex U.S. Q2 net sales of $68.4 million - - Positive CHMP opinion clears way for an expected European approval in October - - Conference call today at 4:30 p.m. EST - CARLSBAD, Calif., Aug. 06, 2019 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the ...
The Formula One Scuderia Ferrari sponsored by AMD (photo via Jisakutech ). A Hedged Portfolio Around A AMD Position Last August, I wrote about the performance of a bulletproof, or hedged, portfolio built around a position in AT&T ( T ) in 2017 and presented a new one, which comp...
During the past trading week (July 22 to 26), a maligned Canadian cannabis firm removed executives from leadership positions at the company. A plan from Quebec to ban most edible cannabis products made headlines, and the launch of a new cannabis exchange-traded fund (ETF) also caught atten...
The European Medicines Agency's advisory group CHMP has adopted a positive opinion recommending approval of GW Pharmaceuticals plc's (NASDAQ: GWPH ) EPIDYOLEX (cannabidiol oral solution) for the adjunctive treatment of seizures associated with Lennox-Gastaut or Dravet syndromes. More new...
If approved cannabidiol oral solution will be the first plant-derived cannabis-based medicine to be approved in Europe for the treatment of any form of epilepsy GW’s cannabidiol oral solution contains highly purified, plant-derived cannabidiol (CBD), a cannabinoid lacking the ...
GW Pharmaceuticals (NASDAQ: GWPH ) is expected to announce its results on August 7. Sales figures for its epidiolex drug for childhood epilepsies will be a key indicator. Off-label indications may start to give an unexpected boost to the numbers. Sales of sativex should also be closely monitor...
LONDON, July 23, 2019 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will a...
News, Short Squeeze, Breakout and More Instantly...
GW Pharmaceuticals Plc Company Name:
GWPH Stock Symbol:
NASDAQ Market:
GW Pharmaceuticals Plc Website:
The key to investing is “Buy low, sell high”. According to that mantra, periods of weakness are the mother’s milk of future gains. When you see them, you know “this is my chance”. It’s the chance to get involved. This is especially true in industries ...
NetworkNewsWire Editorial Coverage : In May 2013, GW Pharma listed on Nasdaq, selling 3.5 million shares at $8.90 each to investors betting that GW was charting a profitable course as a biotech developing new drugs from cannabis-derived compounds. Legal cannabis was only beginning to gain...
Real Brands Inc (OTCMKTS:RLBD) snuck one under the radar late last week, but investors interested in the CBD and Cannabis space should take note. The company filed its Form 10 with the SEC. In this case, it was a voluntary filing because the company does report having over $10 million o...